跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05671757
NCT05671757招募中1 期

Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)

National Institute of Allergy and Infectious Diseases (NIAID)16 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2023年5月26日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
22
试验地点
16
主要终点
The proportion of participants in the dose escalation phase with at least one Dose Limiting Toxicity (DLT)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS).

Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab according to the following schedule, for a total of 8 doses.

The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase.

详细描述

The trial is a phase 1b open-label study of daratumumab in participants with APS.

The study design is a modification of the 3 + 3 dose escalation scheme. Three daratumumab dose cohorts are planned: 4 mg/kg, 8 mg/kg, and 16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48.

Dose Escalation Phase Dose escalation will proceed according to safety criteria (Dose Limiting Toxicity, DLT) and efficacy criteria (antiphospholipid antibody negativity). An independent safety committee will review the data and approve escalation to the next dose.

The Highest Safe Dose (HSD) is the highest administered dose at which ≤ 1/6 participants experiences a DLT at or prior to week 9.

Expansion Phase Four additional participants will be enrolled and treated at the HSD weekly for 8 doses.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Adults 18 to 70 years of age, inclusive.
  • •The completion of the following vaccinations at least 14 days prior to Visit 0:
  • •At least one dose of the most recently updated COVID-19 vaccine, and
  • •At least one dose of the herpes zoster vaccination series, and
  • •Current seasonal influenza vaccine, if available.
  • •History of APS according to the updated 2006 Sapporo classification criteria, including at least one of the following:
  • •a. Arterial thrombosis, except transient ischemic attack, confirmed by objective validated criteria such as imaging, or b. Venous thrombosis, except superficial thrombophlebitis, confirmed by objective validated criteria such as imaging, or c. Pregnancy morbidity, based on the updated 2006 Sapporo APS classification criteria, or d. Microvascular APS, with at least one of the following: i. Renal biopsy documentation of aPL-associated nephropathy, or ii. Lung biopsy or bronchoalveolar lavage documentation of diffuse alveolar hemorrhage (DAH), or iii. Skin biopsy documentation of livedoid vasculopathy.
  • •History of triple positive aPL within the prior 5 years and at least 12 weeks prior to enrollment, including all of the following:
  • •aCL IgG level > Upper Limit of Normal (ULN), and
  • •aβ2GPI IgG level > ULN, and
  • •Positive LA test.
  • •Confirmation of triple positive aPL at screening, including all of the following:
  • •aCL IgG level ≥ 40 GPL, and
  • •aβ2GPI IgG level ≥ 40 SGU, and
  • •Positive LA test.
  • •Undergoing anticoagulation with warfarin or low molecular weight heparin (LMWH), if there is a history of arterial or venous thrombosis.

排除标准

  • •Inability or unwillingness to give written informed consent.
  • •Inability or unwillingness to comply with study protocol.
  • •Systemic autoimmune diseases other than APS, including but not limited to:
  • •Systemic lupus erythematosus (SLE) meeting the EULAR/ACR classification criteria.
  • •Rheumatoid arthritis meeting the ACR/EULAR classification criteria.
  • •Small, medium, and large vessel vasculitis meeting ACR classification criteria.
  • •Catastrophic APS classification within the prior 90 days.
  • •Acute arterial or venous thrombosis within the prior 30 days.
  • •Use of the following medications:
  • •Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc.
  • •The following within the prior 30 days:
  • •i. Corticosteroids > 10 mg/day prednisone or equivalent. ii. Direct oral anticoagulants (DOACs). iii. Live attenuated vaccines. iv. IVIG or other supplemental immunoglobulin. c. Azathioprine, methotrexate, mycophenolate mofetil, mycophenolate sodium, lefluonomide, or calcineurin inhibitors within the prior 90 days.
  • •d. Cyclophosphamide within the prior 90 days. e. Immunomodulatory or immunosuppressive biologic agents, including belimumab, within the prior 90 days or 5 half-lives, whichever is greater.
  • •f. Investigational agents within the prior 90 days or 5 half-lives, whichever is greater, except for COVID-19 vaccines and medications for prevention or treatment of COVID-19 per FDA Emergency Use Authorization (EUA).
  • •g. Biologic B cell depleting agents including rituximab with any of the following: i. Treatment within the prior 180 days, or ii. CD19+ absolute count < 40/ μl, or iii. Serum IgG <500 mg/dL.
  • •Plasma exchange within the prior 90 days.
  • •Hemodialysis within the prior 90 days.
  • •Major surgical procedure within the prior 60 days.
  • •Known allergy, hypersensitivity, or intolerance to boron, malitol, sorbitol, corticosteroids, monoclonal antibodies including daratumumab, human proteins, or their excipients.
  • •Allergy, intolerance, or contraindication to acyclovir, valacyclovir, and famciclovir.
  • •Active or chronic infection, including the following:
  • •Active bacterial, viral, fungal, or opportunistic infection.
  • •Chronic infection requiring suppressive antibiotic treatment.
  • •Intravenous antibiotics or hospitalization for infection within the prior 30 days.
  • •Evidence of current or prior Mycobacterium tuberculosis infection.
  • •Human immunodeficiency virus (HIV).
  • •Current or prior infection with hepatitis B virus (HBV).
  • •Current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response ≥ 12 weeks.
  • •History of recurrent herpes zoster, or history of herpes zoster ophthalmicus, disseminated herpes zoster, or disseminated herpes simplex.
  • •The following laboratory abnormalities:
  • •ITN093AI: DARE-APS Version 3.0 September 12, 2023 Daratumumab in Primary Antiphospholipid Syndrome
  • •Absolute neutrophil count < 1500/mm
  • •Platelets < 100,000/mm
  • •Hemoglobin (Hgb) < 10 g/dL.
  • •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2x the Upper Limit of Normal (ULN).
  • •Total bilirubin > 2x ULN, except in the case of congenital bilirubinemia then direct bilirubin > 2x ULN.
  • •eGFR < 45 ml/min/1.73 m
  • •History of primary immunodeficiency.
  • •History of solid organ or hematopoietic stem cell transplantation.
  • •Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to Visit
  • •Any of the following conditions with FEV1 < 70% predicted within the prior 90 days:
  • •Chronic obstructive pulmonary disease (COPD).
  • •Pulmonary hypertension.
  • •Adrenal insufficiency.
  • •Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 8.0%.
  • •Concomitant malignancy or history of malignancy, except adequately treated or excised nonmetastatic squamous cell carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.
  • •Clinically significant cardiac disease, including but not limited to:
  • •Myocardial infarction within the prior 6 months, or
  • •Unstable or uncontrolled disease or condition related to or affecting cardiac function, including but not limited to:
  • •i. Unstable angina, or ii. Congestive heart failure, New York Heart Association Class II-IV, or iii. Uncontrolled cardiac arrhythmia.
  • 另有 7 项未显示

研究组 & 干预措施

4 mg/kg Cohort

Experimental

This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

干预措施: Daratumumab (Biological)

16 mg/kg Cohort

Experimental

This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

干预措施: Daratumumab (Biological)

8 mg/kg Cohort

Experimental

This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

干预措施: Daratumumab (Biological)

结局指标

主要结局

The proportion of participants in the dose escalation phase with at least one Dose Limiting Toxicity (DLT)

时间窗: At or before week 9

Proportions will be estimated by dose cohort with 95% confidence intervals derived using the Clopper-Pearson exact method

次要结局

  • The proportion of Grade 2 or higher adverse event (AEs) and serious adverse events (SAEs) related to daratumumab(At or before weeks 9, 24, and 48)
  • The proportion of participants with the following Grade 3 or higher adverse events (AEs) related to daratumumab(At or before weeks 9, 24, and 48.)
  • The proportion of participants with negative Lupus Anticoagulant (LA) test(At week 9)
  • The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels(At week 48 compared to week 0)
  • The proportion of participants with a negative Lupus Anticoagulant (LA) test(At week 48)
  • Change in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels(From weeks 0 to weeks 4, 9, 12, 18, 24, 36 and 48)
  • Change in Anticardiolipin antibodies Immunoglobulin M (aCL IgM) levels(From week 0 to weeks 4, 9, 12, 18, 24, 36 and 48)
  • The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG)(At week 9 compared to week 0)
  • The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels(At week 48 compared to week 0)
  • The proportion of Grade 2 or higher serious adverse event (SAEs) related to daratumumab(At or before weeks 9, 24, and 48)
  • The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein I antibodies (a-beta2GPI IgG) compared to week 0(At week 9)
  • The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels(At week 48 compared to week 0)
  • The proportion of participants with a negative Lupus Anticoagulant (LA) test(At week 48)
  • Change in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels(From weeks 0 to weeks 4, 9, 12, 18, 24, 36 and 48)
  • Change in Anticardiolipin antibodies Immunoglobulin M (aCL IgM) levels(From week 0 to weeks 4, 9, 12, 18, 24, 36 and 48)
  • The proportion of Grade 2 or higher serious adverse event (SAEs) related to daratumumab(At or before weeks 9, 24, and 48)
  • The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein I antibodies (a-beta2GPI IgG) compared to week 0(At week 9)
  • The proportion of participants with the following Grade 3 or higher adverse events (AEs) related to daratumumab(At or before weeks 9, 24, and 48.)
  • The proportion of participants with negative Lupus Anticoagulant (LA) test(At week 9)
  • The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG)(At week 9 compared to week 0)
  • The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels(At week 48 compared to week 0)
  • The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels(At week 9 compared to week 0)
  • The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels(At week 24 compared to week 0)
  • The proportion of participants with a negative Lupus Anticoagulant (LA) test(At weeks 4, 9, 12, 18, 24, 36 and 48)
  • The proportion of participants with a negative Lupus Anticoagulant (LA) test(At week 24)

研究者

申办方类型
Nih
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

已完成
早期 1 期
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney CancerBladder Urothelial CarcinomaMalignant Urinary System NeoplasmMetastatic Kidney CarcinomaStage IV Renal Cell Cancer AJCC V8Clear Cell Renal Cell Carcinoma
NCT03473730M.D. Anderson Cancer Center17
进行中（未招募）
2 期
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaMonoclonal GammopathySmoldering Multiple Myeloma
NCT03236428Dana-Farber Cancer Institute42
已完成
1 期
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy SubjectsHealthy
NCT05285137Cidara Therapeutics Inc.77
进行中（未招募）
2 期
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaRefractory Non-Small Cell Lung Cancer
NCT06015724Georgetown University19
招募中
3 期
Study of Daratumumab (JNJ-54767414 (HuMax® CD38) in Combination with VELCADE, Thalidomide. and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple MyelomaMultiple Myeloma10018865
NL-OMON55990Intergroupe Francophone du Myelome (IFM)300